Business Context and Reporting Period
Company: BioNexus Gene Lab Corp. (BGLC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2025
Business Overview: BGLC operates through three primary segments: trading of industrial chemicals (Chemrex Corporation Sdn. Bhd.), genomic screening services (MRNA Scientific Sdn. Bhd.), and investment holding. The company is incorporated in Wyoming with principal operations in Malaysia. It is listed on the Nasdaq Capital Market under the ticker symbol BGLC.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $2,137,075 | $2,381,851 |
| Gross Profit | $343,493 | $365,031 |
| Gross Margin | 16.1% | 15.3% |
| Net Loss | $(623,327) | $(103,757) |
| Operating Loss | $(618,418) | $(79,028) |
| Cash & Cash Equivalents | $2,089,438 | $4,438,694 |
| Total Assets | $9,479,939 | $10,433,848 |
| Total Liabilities | $1,708,303 | $2,111,044 |
| Working Capital | $4,982,026 | $6,415,877 |
| EPS (Basic & Diluted) | $(0.035) | $(0.006) |
Liquidity: As of March 31, 2025, the company held $1,091,201 in cash and bank balances and $2,504,226 in fixed deposits. Total liquidity exceeded $6 million when including trade receivables and short-term investments. The company reported no long-term debt, with liabilities primarily consisting of trade payables and operating lease obligations.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by 10.3% to $2.14 million. The industrial chemicals segment (Chemrex) saw a 10.3% drop due to market slowdown and Malaysian e-invoicing disruptions. The genomic screening segment (MRNA Scientific) declined 3.1% due to equipment downtime and fewer referrals.
- Increased Operating Expenses: Total operating expenses rose 63.3% to $1.05 million. Sales and marketing expenses surged 251.4% to $540,695, driven by higher director remuneration and new business development contracts at Chemrex. General and administrative expenses increased 24.1% to $391,876.
- Widened Net Loss: Net loss expanded significantly to $623,327 from $103,757 in the prior year, primarily due to the spike in operating expenses and a reduction in "Other Income" (down 54.7% to $91,420) caused by lower fair value gains on investments and interest income.
- Cash Flow Deterioration: Net cash used in operating activities increased to $824,072 from $37,153 in the prior year, reflecting the operational loss and working capital changes.
Guidance, Outlook, and Risks
Management Commentary & Strategy:
- Reverse Stock Split: A 1-for-10 reverse stock split was approved by shareholders in March 2025 and effected on April 7, 2025, to regain Nasdaq compliance (minimum bid price of $1.00). Compliance was confirmed on April 30, 2025.
- Ethereum Treasury Strategy: In March 2025, the Board approved a strategy to hold Ethereum (ETH) as a strategic treasury asset to enhance capital efficiency.
- Strategic Partnerships: The company announced partnerships with ML Tech for Ethereum growth strategies, Shenzhen Rongguang Health Group for cancer screening, and VITARRAY Global for mRNA gene detection services.
Risks and Contingencies:
- Going Concern: The filing states that the company's accumulated deficit of $4.07 million and negative operating cash flows raise substantial doubt about its ability to continue as a going concern within one year. Continued operations depend on securing external financing.
- Internal Control Deficiencies: Management identified a "significant deficiency" in internal controls at the Chemrex subsidiary regarding documentation standards and delegation of authority. A remediation plan is underway.
- Operational Disruptions: The genomic screening segment faces delays due to a key RNA machine being under repair, expected to resume operations in Q2 2025.
Investor Verification Checklist
- Going Concern Status: Verify the company's ability to secure additional financing to cover the $623k quarterly burn rate and accumulated deficit.
- Internal Control Remediation: Monitor the progress of the remediation plan for Chemrex's internal control deficiencies to ensure future financial reporting accuracy.
- Reverse Stock Split Impact: Confirm the post-split trading volume and price stability on Nasdaq following the April 7, 2025, implementation.
- Equipment Repair Timeline: Track the return to service of the RNA machine at MRNA Scientific to assess revenue recovery potential in the diagnostics segment.
- Ethereum Strategy Execution: Review the actual implementation and risk management protocols regarding the new Ethereum treasury holdings.